SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Veradermics announced positive Phase 2 study results for VDPHL01 in female hair loss. The data positions the drug as a potential first FDA-approved oral treatment for this indicati…
Axsome Therapeutics announced the FDA accepted its NDA for AXS-12 to treat cataplexy in narcolepsy, setting a PDUFA target date of May 1, 2027. This regulatory milestone advances t…
Green Thumb Industries Inc. filed an amended and restated certificate of incorporation to update its governance framework. This routine regulatory filing indicates no material chan…
The Federal Board of Governors released minutes from its June 8 and June 17, 2026, discount rate meetings, detailing policy discussions.
Celcuity announced FDA approval for the REVTORPYK targeted therapy to treat HR+/HER2- breast cancer without a PIK3CA mutation. The drug reduced the risk of disease progression or d…
Atrium Therapeutics obtained FDA clearance to launch the Phase 1/2 Corventis trial for the precision cardiology candidate ATR 1072. This regulatory milestone validates the company'…
SBC Medical Group filed an amended and restated certificate of incorporation to update its corporate name and authorized capital structure. This regulatory update defines the issua…
UBS Commercial Mortgage Securitization Corp. filed a Form 8-K with the SEC on July 14, 2026, regarding UBS Commercial Mortgage Trust 2018-C14. The filing confirms the registrant an…
The company filed an amended and restated certificate of incorporation to update governance structures. This regulatory filing outlines new powers for the board of directors.
CervoMed released new analyses from its Phase 2b trial reinforcing neflamapimod's efficacy. The data supports selecting the 50 mg dose for Phase 3, enhancing investor confidence in…
Ausenco Engineering Canada ULC consented to the use of its technical report sections regarding the Grassy Mountain Project in the company's official filings. This document serves a…
D-Wave Quantum has voluntarily transferred its common stock listing from the New York Stock Exchange to Nasdaq. The stock will continue trading under the QBTS ticker symbol.
The company filed an exhibit containing an amended certificate of incorporation, likely regarding stock rights or governance. Market relevance is neutral pending specific operation…
Oncolytics Biotech announced plans to hold a Type D meeting with the FDA to design a registrational study for its REO 033 colorectal cancer trial. This regulatory step targets acce…
BNBX received a delisting determination from Nasdaq for failing to maintain a $1.00 bid price threshold. The company is transitioning its shares to the OTCQB Venture Market startin…
Armata Pharmaceuticals received FDA agreement on the Initial Pediatric Study Plan (iPSP) for AP-SA02 to treat resistant staph infections in children. This regulatory milestone adva…
Q32 Bio announced positive toppline results from the SIGNAL-AA trial, showing a 35.3% mean reduction in SALT score. The data demonstrates a differentiated safety profile and effica…
Trio-Tech filed an exhibit updating its third amended bylaws. This governance document adjusts rules for meetings and directors without immediate operational impact.
The FDA released a proposed rule to modernize drug manufacturing registration. The rule targets distributed manufacturing establishments utilizing a 'hub-and-spoke' model.
United Health Products has partnered with NAMSA to sponsor a new clinical study of its CelluSTAT Hemostatic Gauze to help resolve an outstanding FDA warning letter. This collaborat…